FDA warns about rare vision-loss risk associated with GLP-1 drugs
The FDA is warning that GLP-1 drugs may be associated with a rare condition that can lead to vision loss. The agency says the apparent risk is small and that the available data are mixed, so the warning is intended to raise awareness without establishing a clear causal link.